Black Diamond Therapeutics announced positive updated Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, showing an 86% CNS objective response rate and median progression-free survival (mPFS) double that of current EGFR inhibitors. The FDA's End-of-Phase 2 meeting feedback supports a clear path to a pivotal Phase 3 trial and potential accelerated approval based on CNS response. The company plans to start a global Phase 3 trial in mid-2027, enrolling 300 patients with untreated brain metastases, comparing silevertinib to standard treatments. Black Diamond holds $102 million in cash, expected to fund operations into late 2028.
Black Diamond Therapeutics' recent Phase 2 update on silevertinib in NSCLC patients provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: out of 150 priced US health-sector stocks, 76 rose and 58 fell. Notable movers include TVTX at USD 50.50 with a -2.19% change and an 8-day typical hold time, ABEO at USD 2.59 up 1.97% with 71% buy order activity and a 24-day hold, and HIMS at USD 22.54 down 1.77% with 100% buy order activity and a 24-day hold.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
